Description
Prostate specific membrane antigen (PSMA) is a 750 amino-acid, type II glycoprotein highly expressed in prostate adenocarcinoma cells. It is associated with high grade, metastatic prostate cancer. Computer-based algorithms have been used to predict possible PSMA peptides capable of stimulating specific CD8 T Cells restricted by HLA-A2. To date, only one peptide (PSMA27-35 : VLAGGFFLL) can induce specific CD8 T cells capable of recognizing prostate tumor cells that express PSMA and HLA-A2. Ignyte Bio offers the Antigen-Specific CD8 T Cells (ASpecT) specific for the PSMA27-35 : (VLAGGFFLL) peptide, restricted by HLA-A2 protein.